IE
SLS icon

Israel Englander’s SELLAS Life Sciences SLS Stock Holding History

Israel Englander’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.4M Buy
906,000
+280,000
+45% +$1.93M ﹤0.01% 2002
2026
Q1 		$2.65M Buy
+626,000
New +$2.8M ﹤0.01% 3600

Other funds holding SLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 374.31% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Israel Englander's SLS Position: Q2 2026 in Review

Israel Englander sold out of SELLAS Life Sciences (SLS) in Q2 2026, closing a stake of 159,524 shares — an estimated $1.1M sold.

Israel Englander first reported a position in SLS in Q4 2016 and held it in 15 quarters. The position peaked at $5.23M in Q4 2025. 190 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

  • Israel Englander reported no remaining SELLAS Life Sciences position as of Q2 2026 after selling out during the quarter.
  • Israel Englander sold 159,524 SELLAS Life Sciences shares in Q2 2026, an estimated $1.1M.
  • Israel Englander first reported a position in SELLAS Life Sciences in Q4 2016 and held it in 15 quarters.
  • Israel Englander's SELLAS Life Sciences position peaked at $5.23M in Q4 2025.
  • 190 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.